UniProt Q15569 · PDB · AlphaFold · Substrate: Cofilin 2 + Mn · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dabrafenib | 97.0% | 3.0% | 94.74 | 0.633 |
| 2 | Dasatinib | 89.8% | 10.2% | 87.97 | 0.699 |
| 3 | Lorlatinib | 68.2% | 31.8% | 97.24 | 0.694 |
| 4 | Repotrectinib | 66.7% | 33.3% | 84.21 | 0.608 |
| 5 | Crizotinib | 50.3% | 49.7% | 91.39 | 0.581 |
| 6 | Canertinib | 35.2% | 64.8% | 96.49 | 0.671 |
| 7 | Ponatinib | 30.0% | 70.0% | 78.23 | 0.534 |
| 8 | Erdafitinib | 26.6% | 73.4% | 95.71 | 0.737 |
| 9 | Vemurafenib | 24.1% | 75.9% | 96.49 | 0.598 |
| 10 | Gilteritinib | 24.0% | 76.0% | 88.97 | 0.506 |
| 11 | Everolimus | 15.8% | 84.2% | 100.00 | 0.706 |
| 12 | Encorafenib | 15.5% | 84.5% | 98.50 | 0.755 |
| 13 | Ruxolitinib | 15.0% | 85.0% | 98.25 | 0.592 |
| 14 | Lenvatinib | 13.4% | 86.6% | 97.74 | 0.726 |
| 15 | Lapatinib | 13.1% | 86.9% | 99.25 | 0.616 |
| 16 | Nilotinib | 12.2% | 87.8% | 96.49 | 0.765 |
| 17 | Bosutinib | 11.8% | 88.2% | 87.22 | 0.555 |
| 18 | Axitinib | 11.6% | 88.4% | 93.23 | 0.688 |
| 19 | Temsirolimus | 11.5% | 88.5% | 100.00 | 0.740 |
| 20 | Afatinib | 11.2% | 88.8% | 98.50 | 0.709 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.24
- Epithelial log2(TPM+1): 4.03
- Fold change: 0.21
- Status: No significant change
High-confidence drugs
- Dabrafenib — inh 97.0% · KISS 39.56
- Dasatinib — inh 89.8% · KISS 31.24
- Lorlatinib — inh 68.2% · KISS 14.56
Selectivity landscape vs inhibition on TESK1
Each point is one of the 92 approved drugs; color = inhibition % on TESK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…